These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 12629931

  • 1. Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
    Yamamoto DS, Viale PH.
    Clin J Oncol Nurs; 2003; 7(1):21-9. PubMed ID: 12629931
    [Abstract] [Full Text] [Related]

  • 2. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS.
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. COX-2 inhibitors.
    Brooks PM, Day RO.
    Med J Aust; 2000 Oct 16; 173(8):433-6. PubMed ID: 11090038
    [Abstract] [Full Text] [Related]

  • 6. Celecoxib: a COX-2 inhibitor.
    Andrews SA, Wallace CK, Davis RL.
    Am J Manag Care; 1999 Apr 16; 5(4):511-8; quiz 522-4. PubMed ID: 10387389
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [The cardiovascular safety of cyclooxygenase-2 (COX-2) inhibitors].
    Hasdai D, Gottlieb S, Godbourt U, Hod H, Kaluski E.
    Harefuah; 2002 Oct 16; 141(10):922-4. PubMed ID: 12420602
    [No Abstract] [Full Text] [Related]

  • 9. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A.
    Rheumatology (Oxford); 2002 Apr 16; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
    Lee MC, Lee S, Suh DC, Kim J, Kong SX, Korea Arthritis Study Group.
    Curr Med Res Opin; 2003 Apr 16; 19(7):597-602. PubMed ID: 14606981
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
    Moyad MA.
    Semin Urol Oncol; 2001 Nov 16; 19(4):306-16. PubMed ID: 11769882
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN, Callaghan R, Allen ME, Rowe IF.
    Rheumatology (Oxford); 2005 Jul 16; 44(7):921-4. PubMed ID: 15827035
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA.
    Cancer Res; 2000 Sep 15; 60(18):5040-4. PubMed ID: 11016626
    [Abstract] [Full Text] [Related]

  • 20. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
    Pascucci RA.
    J Am Osteopath Assoc; 2002 Sep 15; 102(9):487-9. PubMed ID: 12361181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.